Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study
Clinical Pharmacology in Drug Development · 2023
DOI: 10.1002/cpdd.1293 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2023. Verfasst von Sandy Van Hemelryck und 4 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Pharmaceutica NV, Beerse, Belgium. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV-1, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben.
Abstract (Originalsprache)
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a fixed‐dose combination (FDC) for the treatment of HIV‐1 infection in adults and adolescents weighing 40 kg or greater. This Phase 1, randomized, open‐label, 2‐treatment, 2‐sequence, 4‐period replicate crossover study (NCT04661397) evaluated the pivotal bioequivalence of a pediatric D/C/F/TAF 675/150/200/10‐mg FDC compared with coadministration of the separate commercially available formulations in healthy adults under fed conditions. During each period, participants received either a single oral dose of D/C/F/TAF 675/150/200/10‐mg FDC (test) or a single oral dose of darunavir 600 and 75 mg, cobicistat 150 mg, and emtricitabine/tenofovir alafenamide 200/10‐mg FDC (reference). Thirty‐seven participants were randomly assigned to one of 2 treatment sequence groups: test‐reference‐reference‐test or reference‐test‐test‐reference, with 7 days or more washout between periods. The 90% confidence intervals of the geometric mean ratios for maximum plasma concentration, area under the concentration–time curve from time zero to last measurable concentration, and area under the concentration–time curve extrapolated to infinity for darunavir, cobicistat, emtricitabine, and tenofovir alafenamide fell within conventional bioequivalence limits (80%–125%). No Grade 3/4 adverse events, serious adverse events, or deaths occurred. In conclusion, administration of D/C/F/TAF 675/150/200/10‐mg FDC was bioequivalent to coadministration of the separate commercially available formulations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Janssen Pharmaceutica NV, Beerse, Belgium.
- Janssen Research & Development, LLC, Spring House, PA, USA.
Zitieren
APA
Van Hemelryck, S., Van Landuyt, E., Ariyawansa, J., Vanveggel, S., & Palmer, M. (2023). Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1293
Vancouver
Van Hemelryck S, Van Landuyt E, Ariyawansa J, Vanveggel S, Palmer M. Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study. Clinical Pharmacology in Drug Development. 2023. doi:10.1002/cpdd.1293
BibTeX
@article{VanHemelryck2023,
author = {Van Hemelryck, Sandy and Van Landuyt, Erika and Ariyawansa, Jay and Vanveggel, Simon and Palmer, Martyn},
title = {Bioequivalence of a Pediatric Fixed‐Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open‐Label, Randomized, Replicate Crossover Study},
journal = {Clinical Pharmacology in Drug Development},
year = {2023},
doi = {10.1002/cpdd.1293}
}
EUVIMED